{"id":5340,"date":"2018-12-07T03:13:32","date_gmt":"2018-12-07T03:13:32","guid":{"rendered":"http:\/\/41j.com\/blog\/?p=5340"},"modified":"2018-12-07T21:56:56","modified_gmt":"2018-12-07T21:56:56","slug":"gene-editing-companies-december-2018","status":"publish","type":"post","link":"https:\/\/41j.com\/blog\/2018\/12\/gene-editing-companies-december-2018\/","title":{"rendered":"Gene Editing Companies (December 2018)"},"content":{"rendered":"

I’ve put together the list of Gene\/Genome\/DNA editing business below. I’ve listed companies who seem to be primarily service or research apps businesses below the main list, however the distinction isn’t always clear as they may have some novel technology as well as.<\/p>\n

These are all the editing companies I’m aware of. If you know of any more, or have any corrections for the list, let me know!<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Company<\/td>\nStage<\/td>\nRaised<\/td>\nApplication<\/td>\nLocation<\/td>\nSite\/Info<\/td>\n<\/tr>\n
Agenovir<\/td>\n Acquired<\/td>\n 10.6M<\/td>\n antiviral therapies<\/td>\n San Diego – USA<\/td>\n report<\/a><\/td>\n<\/tr>\n
ATGC Inc<\/td>\nIPO<\/td>\n<\/td>\n nanoparticle delivery system<\/td>\n Ann Arbor – USA<\/td>\n grant info<\/a><\/td>\n<\/tr>\n
Beam Therapeutics<\/td>\n Series A<\/td>\n 87M<\/td>\n Base editor human therapeutics<\/td>\n Cambridge – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Biopalette<\/td>\nSeed?<\/td>\n~2M<\/td>\nNon-cutting Editing tech<\/td>\nKobe – Japan<\/td>\nsite<\/a><\/td>\n<\/tr>\n
Calyxt<\/td>\n IPO<\/td>\n 61.4M<\/td>\n TALEN plant genome editing<\/td>\n Minnesota – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Caribou Biosciences<\/td>\n Series B<\/td>\n 74.6M<\/td>\n Foundational CRISPR-Cas9 IP<\/td>\n Bay Area – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Celdara Medical<\/td>\n<\/td>\n<\/td>\n CRISPR HIV Therapy<\/td>\n New Hampshire – USA<\/td>\n grant info<\/a><\/td>\n<\/tr>\n
CELL MICROSYSTEMS INC.<\/td>\n<\/td>\n<\/td>\n High throughput CRISPR cell-line production<\/td>\nNorth Carolina – USA<\/td>\n grant info<\/a><\/td>\n<\/tr>\n
Cellectis<\/td>\nIPO<\/td>\n<\/td>\n CAR-T (gene edited) for Cancer therapy<\/td>\n France<\/td>\nsite<\/a><\/td>\n<\/tr>\n
Cibus<\/td>\n Series C<\/td>\n 200M<\/td>\n Gene editing crop development<\/td>\n San Diego<\/td>\n site<\/a><\/td>\n<\/tr>\n
Crispa Therapeutics<\/td>\n Series B<\/td>\n 127M<\/td>\n Foundational CRISPR IP – Human therapeutics<\/td>\nCambridge – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Desktop Genetics<\/td>\n Series A?<\/td>\n 6.9M<\/td>\n AI for CRISPR design<\/td>\n London – UK<\/td>\n site<\/a><\/td>\n<\/tr>\n
Edigene<\/td>\n Series A<\/td>\n 15M<\/td>\n Engineered CRISPR\/Cas9<\/td>\n Tokyo – Japan<\/td>\n site<\/a><\/td>\n<\/tr>\n
Edit Force<\/td>\n Series A<\/td>\n ~4.5M<\/td>\nPPR protein engineering tech.<\/td>\n Fukuoka – Japan<\/td>\n site<\/a><\/td>\n<\/tr>\n
Editas Medicine<\/td>\n IPO<\/td>\n 210M<\/td>\n CRISPR for human therapeutics<\/td>\n Cambridge – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
eGenesis Bio<\/td>\n Series A<\/td>\n 40M<\/td>\n Edited animals for xenotransplantation<\/td>\n Cambridge – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Eligo Bioscience (fka PhageX)<\/td>\n Series A<\/td>\n 22.9M<\/td>\n Bacteriophage delivered CRISPR anti-microbials<\/td>\n Paris – France<\/td>\n site<\/a><\/td>\n<\/tr>\n
Evotec AG<\/td>\n IPO<\/td>\n<\/td>\n CRISPR licensee – research tools<\/td>\n Hamburg – Germany<\/td>\n report<\/a><\/td>\n<\/tr>\n
Excision BioTherapeutics<\/td>\n Seed<\/td>\n 10M<\/td>\n Human therapeutics<\/td>\n Pennsylvania – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Exonics Therapeutics<\/td>\n Series A<\/td>\n 45M<\/td>\n SingleCut CRISPR for human therapeutics (neuromuscular)<\/td>\n Watertown – MA – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
GenEdit<\/td>\n pre-seed?<\/td>\n<\/td>\n CRISPR (+other) therapeutics with nanoparticle delivery<\/td>\n Berkeley – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Homology Medicines<\/td>\n IPO<\/td>\n 127M<\/td>\n Homologous recombination for human therapeutics<\/td>\n Bedford – MA – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Inari Agriculture<\/td>\n Series B<\/td>\n 40M<\/td>\n Editing for Agriculture applications<\/td>\n Cambridge – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
indee labs<\/td>\n Seed<\/td>\n 5.1M<\/td>\n Vortex shedding gene delivery for editing apps<\/td>\n San Francisco – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Inscripta<\/td>\n Series C<\/td>\n 84.4M<\/td>\n Developing new classes of CRISPR endonuclease novel editing tech.<\/td>\n Boulder – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Intellia Therapeutics<\/td>\n Series B<\/td>\n 85M<\/td>\n CRISPR human therapeutics<\/td>\n Cambridge – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Ligandal<\/td>\n Seed<\/td>\n 844K<\/td>\n Nanotech delivery platform for CRISPR human therapeutics<\/td>\n San Francisco – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Locus Biosciences<\/td>\n Series A<\/td>\n 26M<\/td>\n CRISPR-engineered bacteriophage cocktails – human therapeutics<\/td>\n North Carolina – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Mammoth Biosciences<\/td>\n Series A<\/td>\n 24.6M<\/td>\n CRISPR-based disease detection (human diagnostics)<\/td>\n San Francisco – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
NextBiotics<\/td>\n Seed<\/td>\n 100K<\/td>\n CRISPR edited bacterophage?<\/td>\n San Francisco – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Pairwise Plants<\/td>\n Series A<\/td>\n 25M<\/td>\n Gene editing for agricultural applications<\/td>\n North Carolina – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Plantedit<\/td>\n Seed<\/td>\n 100K<\/td>\n Gene editing for agricultural applications<\/td>\n Indiana – USA.<\/td>\nsite<\/a><\/td>\n<\/tr>\n
Poseida Therapeutics<\/td>\n Series B<\/td>\n 84.5M<\/td>\n Novel Cas-CLOVER editing for human therapeutic applications<\/td>\n San Diego – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Precision BioSciences<\/td>\n Series B<\/td>\n 135.7M<\/td>\n Homing endonuclease based editing platform<\/td>\n North Carolina – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Recombinetics<\/td>\n Series A<\/td>\n 60.9M<\/td>\n xenotransplantation and edit humanized disease models<\/td>\n Minnesota – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Sangamo Therapeutics<\/td>\n IPO<\/td>\n 93.2M<\/td>\n ZFN Gene editing for human therapeutics<\/td>\n Richmond – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Service Businesses<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Company<\/td>\nStage<\/td>\nRaised<\/td>\nApplication<\/td>\nLocation<\/td>\nSite\/Info<\/td>\n<\/tr>\n
Allele Biotechnology<\/td>\n Series B<\/td>\n 10M<\/td>\n Service business<\/td>\n San Diego – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Applied StemCells<\/td>\n Series D<\/td>\n 23.5M<\/td>\n Service business<\/td>\n San Francisco – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
GeneCopoeia<\/td>\n<\/td>\n<\/td>\n CRISPR Service business<\/td>\n Maryland – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
genoway<\/td>\n<\/td>\n<\/td>\n Edited mice etc. Service business<\/td>\n Lyon – France<\/td>\n site<\/a><\/td>\n<\/tr>\n
GenScript<\/td>\n<\/td>\n<\/td>\n CRISPR Service Business<\/td>\n New Jersey – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Horizon Discovery<\/td>\n IPO<\/td>\n<\/td>\n Editing Service Business<\/td>\n Cambridge – UK<\/td>\n site<\/a><\/td>\n<\/tr>\n
HUDSON RIVER BIOTECHNOLOGY BV<\/td>\n IPO<\/td>\n<\/td>\n Editing Service Business<\/td>\n Netherlands<\/td>\n site<\/a><\/td>\n<\/tr>\n
inDroso<\/td>\n<\/td>\n<\/td>\n CRISPR genome edited flies Service Business<\/td>\n Rennes – France<\/td>\n site<\/a><\/td>\n<\/tr>\n
ThermoFisher<\/td>\n<\/td>\n<\/td>\n Service Business<\/td>\n<\/td>\n site<\/a><\/td>\n<\/tr>\n
MaxCyte<\/td>\n IPO<\/td>\n 31.3M<\/td>\n Editing Services and tools<\/td>\n Maryland – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
OriGene<\/td>\n<\/td>\n<\/td>\n CRISPR Service business and products<\/td>\n Maryland – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Sigma Aldrich<\/td>\n<\/td>\n<\/td>\n Service business and tools<\/td>\n<\/td>\n site<\/a><\/td>\n<\/tr>\n
Synthego<\/td>\n Series C<\/td>\n 159.5M<\/td>\n Service Business and tools for editing<\/td>\n Redwood City – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
Taconic Biosciences<\/td>\n<\/td>\n<\/td>\n Service business – CRISPR mouse models<\/td>\n New York – USA<\/td>\n site<\/a><\/td>\n<\/tr>\n
ToolGen<\/td>\n<\/td>\n<\/td>\n Service business -IP holder?<\/td>\n Seoul – Korea<\/td>\n site<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Misc<\/p>\n

BBI Life Sciences: www.bbi-lifesciences.com
\nBenchling – Design tool: site<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

I’ve put together the list of Gene\/Genome\/DNA editing business below. I’ve listed companies who seem to be primarily service or research apps businesses below the main list, however the distinction isn’t always clear as they may have some novel technology as well as. These are all the editing companies I’m aware of. If you know […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[],"class_list":["post-5340","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p1RRoU-1o8","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/41j.com\/blog\/wp-json\/wp\/v2\/posts\/5340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/41j.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/41j.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/41j.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/41j.com\/blog\/wp-json\/wp\/v2\/comments?post=5340"}],"version-history":[{"count":24,"href":"https:\/\/41j.com\/blog\/wp-json\/wp\/v2\/posts\/5340\/revisions"}],"predecessor-version":[{"id":5394,"href":"https:\/\/41j.com\/blog\/wp-json\/wp\/v2\/posts\/5340\/revisions\/5394"}],"wp:attachment":[{"href":"https:\/\/41j.com\/blog\/wp-json\/wp\/v2\/media?parent=5340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/41j.com\/blog\/wp-json\/wp\/v2\/categories?post=5340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/41j.com\/blog\/wp-json\/wp\/v2\/tags?post=5340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}